The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies
- PMID: 40109726
- PMCID: PMC11919916
- DOI: 10.3389/fmed.2025.1513598
The hepatocellular model of fatty liver disease: from current imaging diagnostics to innovative proteomics technologies
Abstract
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a prevalent chronic liver condition characterized by lipid accumulation and inflammation, often progressing to severe liver damage. We aim to review the pathophysiology, diagnostics, and clinical care of MASLD, and review highlights of advances in proteomic technologies. Recent advances in proteomics technologies have improved the identification of novel biomarkers and therapeutic targets, offering insight into the molecular mechanisms underlying MASLD progression. We focus on the application of mass spectrometry-based proteomics including single cell proteomics, proteogenomics, extracellular vesicle (EV-omics), and exposomics for biomarker discovery, emphasizing the potential of blood-based panels for noninvasive diagnosis and personalized medicine. Future research directions are presented to develop targeted therapies and improve clinical outcomes for MASLD patients.
Keywords: MASH; MASLD; exposomics; proteogenomics; proteomics; single-cell.
Copyright © 2025 Hernandez, Garcia-Rodriguez, Arriaga, Perez, Bala, Leandro, Diego, Almeida, Parsons, Manusov and Galan.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Unraveling Metabolic Dysfunction-Associated Steatotic Liver Disease Through the Use of Omics Technologies.Int J Mol Sci. 2025 Feb 13;26(4):1589. doi: 10.3390/ijms26041589. Int J Mol Sci. 2025. PMID: 40004054 Free PMC article. Review.
-
Diagnostics and omics technologies for the detection and prediction of metabolic dysfunction-associated steatotic liver disease-related malignancies.Metabolism. 2024 Dec;161:156015. doi: 10.1016/j.metabol.2024.156015. Epub 2024 Aug 30. Metabolism. 2024. PMID: 39216799 Review.
-
Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective.Lipids Health Dis. 2025 Jan 7;24(1):5. doi: 10.1186/s12944-024-02396-3. Lipids Health Dis. 2025. PMID: 39773634 Free PMC article. Review.
-
Single-cell landscape of peripheral immune cells in MASLD/MASH.Hepatol Commun. 2025 Apr 21;9(5):e0643. doi: 10.1097/HC9.0000000000000643. eCollection 2025 May 1. Hepatol Commun. 2025. PMID: 40257301 Free PMC article.
-
Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease.Front Physiol. 2025 Mar 17;16:1562848. doi: 10.3389/fphys.2025.1562848. eCollection 2025. Front Physiol. 2025. PMID: 40166716 Free PMC article. Review.
Cited by
-
Effects of Prebiotics Inulin and Oat β-Glucan on Colonic Architecture and Hepatic Proteome in Mice with Circadian-Disruption-Aggravated Metabolic Dysfunction-Associated Steatohepatitis.Nutrients. 2025 Jul 7;17(13):2245. doi: 10.3390/nu17132245. Nutrients. 2025. PMID: 40647350 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources